Trial Profile
A Phase 2 Clinical Study to Evaluate Daily Oral Doses of LY500307 for 24 Weeks in Men With Lower Urinary Tract Symptoms (LUTS) and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia (BPH)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 14 Oct 2021
Price :
$35
*
At a glance
- Drugs Erteberel (Primary)
- Indications Benign prostatic hyperplasia; Lower urinary tract symptoms
- Focus Pharmacogenomic; Therapeutic Use
- Acronyms BPAE
- 14 Oct 2021 This trial has been completed in France (End Date: 18 Oct 2011), according to European Clinical Trials Database record.
- 19 Oct 2012 New source identified and integrated (German Clinical Trials Register; DRKS00004128).
- 11 Oct 2011 Planned end date changed from 1 Oct 2012 to 1 Oct 2011 as reported by ClinicalTrials.gov.